ZyVersa Therapeutics ( (ZVSA) ) has released a notification of late filing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ZyVersa Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The primary reason for this delay is the need for additional time to complete management’s review of the company’s quarter-end consolidated financial statements and related disclosures. ZyVersa Therapeutics expects to file the delayed report within the five-day extension period allowed under Rule 12b-25. The company anticipates significant changes in its financial results, particularly a notable increase in net loss due to an $18.6 million non-cash impairment charge related to in-process research and development. The notification was signed by Peter Wolfe, the Chief Financial Officer, indicating ongoing compliance efforts.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
Average Trading Volume: 45,597
Technical Sentiment Signal: Sell
Current Market Cap: $1.21M
For a thorough assessment of ZVSA stock, go to TipRanks’ Stock Analysis page.